Education
About Us
Working with TipRanks
Follow Us
Heart Test Laboratories, Inc. (HSCS)
NASDAQ:HSCS
HSCS Stock Chart & Stats
$3.35
-$0.05(-1.44%)
At close: 4:00 PM EST
$3.35
-$0.05(-1.44%)
Day’s Range― - ―
52-Week Range$2.01 - $6.47
Previous CloseN/A
Volume8.49K
Average Volume (3M)58.86K
Market Cap
$10.17M
Enterprise Value-$1.07B
Total Cash (Recent Filing)$1.95M
Total Debt (Recent Filing)$876.24K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Mar 12, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding3,178,207
10 Day Avg. Volume93,774
30 Day Avg. Volume58,857
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)16.05
Price to Sales (P/S)757.08
P/FCF Ratio-0.44
Enterprise Value/Market Cap-104.85
Enterprise Value/Revenue-123.01K
Enterprise Value/Gross Profit18.17K
Enterprise Value/Ebitda131.84
Forecast
1Y Price Target
$10.60Price Target Upside216.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cloud Platform Market OpportunityMyoVista Insights targeting hospital ECG management represents a large addressable market that can generate recurring software revenue if hospitals adopt the platform at scale.
Regulatory Approval And Device RolloutFDA approval of the MyoVista device combined with the phased rollout of the MyoVista Insights platform could drive clinical adoption and expand the company's diagnostic footprint.
Reimbursement And Unit EconomicsHigher reimbursement for the MyoVista procedure alongside strong gross margin potential for disposables and software can produce attractive unit economics and improved profitability per use.
Bears Say
Execution And Commercialization RiskChallenges in scaling sales, securing hospital reference sites, and executing the commercialization plan could delay revenue growth and weigh on the stock if targets are missed.
Financing RequirementsSubstantial additional capital is likely needed to fund commercialization after regulatory milestones, creating financing risk and possible pressure on the balance sheet.
Share Count DilutionConversion of preferred securities and exercise of warrants could materially increase outstanding shares, diluting current shareholders and reducing per-share valuation.
Heart Test Laboratories, Inc. News
HSCS FAQ
What was Heart Test Laboratories, Inc.’s price range in the past 12 months?
Heart Test Laboratories, Inc. lowest stock price was $2.01 and its highest was $6.47 in the past 12 months.
What is Heart Test Laboratories, Inc.’s market cap?
Heart Test Laboratories, Inc.’s market cap is $10.17M.
When is Heart Test Laboratories, Inc.’s upcoming earnings report date?
Heart Test Laboratories, Inc.’s upcoming earnings report date is Mar 12, 2026 which is in 53 days.
How were Heart Test Laboratories, Inc.’s earnings last quarter?
Heart Test Laboratories, Inc. released its earnings results on Dec 15, 2025. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$1.275 by $0.505.
Is Heart Test Laboratories, Inc. overvalued?
According to Wall Street analysts Heart Test Laboratories, Inc.’s price is currently Undervalued.
Does Heart Test Laboratories, Inc. pay dividends?
Heart Test Laboratories, Inc. does not currently pay dividends.
What is Heart Test Laboratories, Inc.’s EPS estimate?
Heart Test Laboratories, Inc.’s EPS estimate is -0.88.
How many shares outstanding does Heart Test Laboratories, Inc. have?
Heart Test Laboratories, Inc. has 3,178,207 shares outstanding.
What happened to Heart Test Laboratories, Inc.’s price movement after its last earnings report?
Heart Test Laboratories, Inc. reported an EPS of -$0.77 in its last earnings report, beating expectations of -$1.275. Following the earnings report the stock price went down -6.478%.
Which hedge fund is a major shareholder of Heart Test Laboratories, Inc.?
Currently, no hedge funds are holding shares in HSCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heart Test Laboratories, Inc.
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
HSCS Stock 12 Month Forecast
Average Price Target
$10.60
▲(216.42% Upside)
Technical Analysis
Strata Skin Sciences
―
Biomerica
―
PAVmed
―
Tenon Medical, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
2.49% Insiders
0.36% Mutual Funds
4.17% Other Institutional Investors
92.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---